NR1H4 and Hyperglycemia: Although these liver effects of FXR activation may prevent fasting hyperglycemia, it does not sufficiently explain the increased insulin sensitivity and glucose disposal in FXR agonist-treated mice as determined by glucose and insulin tolerance tests.